Announced
Completed
Synopsis
PetIQ, a pet medication and wellness company, completed the acquisition of Capstar, an oral tablet for the treatment of flea infestations on dogs, puppies, cats and kittens, for $95m. “We are excited to complete this transaction and believe Capstar’s® highly profitable product offering fits perfectly with PetIQ’s product offerings. This further advances our leadership position in helping pet parents find affordable animal health products for their pets. In a dynamic operating environment, we are very pleased that Capstar® has generated strong results year to date, increasing our confidence in its accretive growth opportunities and long-term value creation," Cord Christensen, PetIQ Chairman and CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.